## Bernard Cuenoud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/57481/publications.pdf

Version: 2024-02-01

37 papers

2,015 citations

279798 23 h-index 36 g-index

39 all docs 39 docs citations

39 times ranked 1708 citing authors

#	Article	IF	CITATIONS
1	A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6â€month RCT. Alzheimer's and Dementia, 2021, 17, 543-552.	0.8	92
2	A ketogenic supplement improves white matter energy supply and processing speed in mild cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12217.	3.7	16
3	Modulation of cerebral ketone metabolism following traumatic brain injury in humans. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 177-186.	4.3	35
4	Medium Chain Triglycerides Modulate the Ketogenic Effect of a Metabolic Switch. Frontiers in Nutrition, 2020, 7, 3.	3.7	25
5	Improved brain energetics and cognition after a 6â€month ketogenic intervention in mild cognitive impairment: Final results of the Benefic Trial. Alzheimer's and Dementia, 2020, 16, e037961.	0.8	O
6	Metabolism of Exogenous D-Beta-Hydroxybutyrate, an Energy Substrate Avidly Consumed by the Heart and Kidney. Frontiers in Nutrition, 2020, 7, 13.	3.7	44
7	Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms. Nutrients, 2020, 12, 1014.	4.1	12
8	Brain NAD Is Associated With ATP Energy Production and Membrane Phospholipid Turnover in Humans. Frontiers in Aging Neuroscience, 2020, 12, 609517.	3.4	23
9	Discovery and validation of temporal patterns involved in human brain ketometabolism in cerebral microdialysis fluids of traumatic brain injury patients. EBioMedicine, 2019, 44, 607-617.	6.1	17
10	Effects of interesterified lipid design on the short/medium chain fatty acid hydrolysis rate and extent ( <i>in vitro</i> ). Food and Function, 2019, 10, 4166-4176.	4.6	14
11	Nutrient pattern analysis in critically ill patients using Omics technology (NAChO) – Study protocol for a prospective observational study. Medicine (United States), 2019, 98, e13937.	1.0	1
12	Nutritional Ketosis Increases NAD+/NADH Ratio in Healthy Human Brain: An in Vivo Study by 31P-MRS. Frontiers in Nutrition, 2018, 5, 62.	3.7	62
13	Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5445-5450.	2.2	46
14	The Identification of Indacaterol as an Ultralong-Acting Inhaled $\hat{l}^2$ <sub>2</sub> -Adrenoceptor Agonist. Journal of Medicinal Chemistry, 2010, 53, 3675-3684.	6.4	90
15	Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties?. European Journal of Pharmaceutical Sciences, 2009, 38, 533-547.	4.0	84
16	Interaction kinetics of salmeterol with egg phosphatidylcholine liposomes by surface plasmon resonance. Analytical Biochemistry, 2009, 385, 215-223.	2.4	12
17	Targeted Gene Knock In and Sequence Modulation Mediated by a Psoralen-linked Triplex-forming Oligonucleotide*. Journal of Biological Chemistry, 2008, 283, 11244-11252.	3.4	39
18	Extensive Sugar Modification Improves Triple Helix Forming Oligonucleotide Activity in Vitro but Reduces Activity in Vivo. Biochemistry, 2007, 46, 10222-10233.	2.5	26

#	Article	IF	Citations
19	Targeted Cross-linking of the Human β-Globin Gene in Living Cells Mediated by a Triple Helix Forming Oligonucleotideâ€. Biochemistry, 2006, 45, 1970-1978.	2.5	36
20	In Vitro and in Vivo Pharmacological Characterization of $5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled \hat{I}^22 Adrenoceptor Agonist with a 24-h Duration of Action. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 762-770.$	2.5	155
21	The Development of Bioactive Triple Helix-Forming Oligonucleotides. Annals of the New York Academy of Sciences, 2005, 1058, 119-127.	3.8	29
22	Importance of Clustered 2â€~-O-(2-Aminoethyl) Residues for the Gene Targeting Activity of Triple Helix-Forming Oligonucleotides‡. Biochemistry, 2004, 43, 1343-1351.	2.5	43
23	Gene Targeting by Triple Helix-Forming Oligonucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 141-153.	3.8	14
24	Cell Cycle Modulation of Gene Targeting by a Triple Helix-forming Oligonucleotide. Journal of Biological Chemistry, 2003, 278, 11072-11077.	3.4	58
25	Minimum Number of 2â€~-O-(2-Aminoethyl) Residues Required for Gene Knockout Activity by Triple Helix Forming Oligonucleotides. Biochemistry, 2002, 41, 7716-7724.	2.5	49
26	Determination of Aliphatic Side-Chain Conformation Using Cross-Correlated Relaxation: Application to an Extraordinarily Stable 2â€~aminoethoxy-Modified Oligonucleotide Triplex. Journal of the American Chemical Society, 2001, 123, 7364-7370.	13.7	26
27	Inhibition of Interleukin-4- and CD40-induced IgE Germline Gene Promoter Activity by 2′-Aminoethoxy-modified Triplex-forming Oligonucleotides. Journal of Biological Chemistry, 2001, 276, 11759-11765.	3.4	23
28	Targeted Gene Knockout by $2\hat{a}\in^2$ -O-Aminoethyl Modified Triplex Forming Oligonucleotides. Journal of Biological Chemistry, 2001, 276, 28991-28998.	3.4	44
29	Synthesis and hybridization properties of polyamide based nucleic acid analogues incorporating pyrrolidine-derived nucleoamino acids. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 929-933.	2.2	18
30	Dual Recognition of Double-Stranded DNA by 2′-Aminoethoxy-Modified Oligonucleotides. Angewandte Chemie - International Edition, 1998, 37, 1288-1291.	13.8	131
31	Dual Recognition of Double-Stranded DNA by 2 -Aminoethoxy-Modified Oligonucleotides: The Solution Structure of an Intramolecular Triplex Obtained by NMR Spectroscopy. Biochemistry, 1998, 37, 17714-17725.	2.5	67
32	A DNA metalloenzyme with DNA ligase activity. Nature, 1995, 375, 611-614.	27.8	424
33	DNA Bending and Binding by Metallo-Zipper Models of bZIP Proteins. Journal of the American Chemical Society, 1995, 117, 8899-8907.	13.7	39
34	A new strategy for directed protein cleavage. Tetrahedron Letters, 1992, 33, 895-898.	1.4	78
35	A general scheme for incorporating nonnatural functionality into peptides. Tetrahedron Letters, 1991, 32, 3325-3328.	1.4	6
36	Synthesis of N-α-boc-N-ε-tribenzyl EDTA-L-lysine. An amino acid analogue suitable for solid phase peptide synthesis. Tetrahedron, 1991, 47, 2535-2542.	1.9	9

#	Article	IF	CITATIONS
37	Site-specific cleavage of the protein calmodulin using a trifluoperazine-based affinity reagent. Journal of the American Chemical Society, 1990, 112, 3247-3249.	13.7	127